| Parklands Care Center | |
| 1000 Sw 16th Ave, Gainesville, Florida 32601 | |
| (352) 376-2461 | |
| Name | Parklands Care Center |
|---|---|
| Location | 1000 Sw 16th Ave, Gainesville, Florida |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 120 |
| Occupancy Rate | 87.33% |
| Medicare ID (CCN) | 105638 |
| Legal Business Name | Parklands Facility Inc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1821105677 |
| Organization Name | GAINESVILLE REHABILITATION AND NURSING CENTER LLC |
| Doing Business As | PARKLANDS REHABILITATION AND NURSING CENTER |
| Address | 1000 Sw 16th Ave, Gainesville, FL 32601 |
| Phone Number | 352-376-2461 |
News Archive
Two drugs tested in a larger trial did not improve kidney function in acute heart failure patients, contrary to results of smaller studies. The results were presented today at the American Heart Association's Scientific Sessions 2013 in Dallas and simultaneously published in the Journal of the American Medical Association. Previous smaller studies showed that low-dose dopamine or low-dose nesiritide could improve kidney function and reduce fluid overload that is often present in hospitalized acute heart failure patients by increasing urine production.
New statistics show a big increase in the number of cancers detected by breast screening. In 2003/04 over 14% more cancers were detected compared to the previous year with over 11,000 women having breast cancer detected and treated following screening for the disease. Since 2001 the total number of cancers detected through breast screening has risen by nearly a third.
Immusoft Corporation, a Seattle-Wash.-based cell therapy company, announced today that the U.S. Food and Drug Administration (FDA) has granted it Rare Pediatric Disease Designation (RPDD) for Iduronicrin genleukocel-T, Immusoft's Sleeping Beauty transposon-engineered autologous plasmablasts for the expression and delivery of alpha-L-iduronidase (IDUA) to treat Mucopolysaccharidosis type I (MPS I).
Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.
Many patients worldwide are going to receive major abdomen surgery or intestine transplantation every year and expect to be afflicted with liver injury afterwards.
› Verified 6 days ago
| NPI Number | 1881081180 |
| Organization Name | PARKLANDS FACILITY INC |
| Doing Business As | PARKLANDS CARE CENTER |
| Address | 1000 Sw 16th Ave, Gainesville, FL 32601 |
| Phone Number | 352-376-2461 |
News Archive
Two drugs tested in a larger trial did not improve kidney function in acute heart failure patients, contrary to results of smaller studies. The results were presented today at the American Heart Association's Scientific Sessions 2013 in Dallas and simultaneously published in the Journal of the American Medical Association. Previous smaller studies showed that low-dose dopamine or low-dose nesiritide could improve kidney function and reduce fluid overload that is often present in hospitalized acute heart failure patients by increasing urine production.
New statistics show a big increase in the number of cancers detected by breast screening. In 2003/04 over 14% more cancers were detected compared to the previous year with over 11,000 women having breast cancer detected and treated following screening for the disease. Since 2001 the total number of cancers detected through breast screening has risen by nearly a third.
Immusoft Corporation, a Seattle-Wash.-based cell therapy company, announced today that the U.S. Food and Drug Administration (FDA) has granted it Rare Pediatric Disease Designation (RPDD) for Iduronicrin genleukocel-T, Immusoft's Sleeping Beauty transposon-engineered autologous plasmablasts for the expression and delivery of alpha-L-iduronidase (IDUA) to treat Mucopolysaccharidosis type I (MPS I).
Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.
Many patients worldwide are going to receive major abdomen surgery or intestine transplantation every year and expect to be afflicted with liver injury afterwards.
› Verified 6 days ago
| NPI Number | 1942958384 |
| Organization Name | PARKLANDS NURSING AND REHAB LLC |
| Address | 1000 Sw 16th Ave, Gainesville, FL 32601 |
| Phone Number | 352-376-2461 |
News Archive
Two drugs tested in a larger trial did not improve kidney function in acute heart failure patients, contrary to results of smaller studies. The results were presented today at the American Heart Association's Scientific Sessions 2013 in Dallas and simultaneously published in the Journal of the American Medical Association. Previous smaller studies showed that low-dose dopamine or low-dose nesiritide could improve kidney function and reduce fluid overload that is often present in hospitalized acute heart failure patients by increasing urine production.
New statistics show a big increase in the number of cancers detected by breast screening. In 2003/04 over 14% more cancers were detected compared to the previous year with over 11,000 women having breast cancer detected and treated following screening for the disease. Since 2001 the total number of cancers detected through breast screening has risen by nearly a third.
Immusoft Corporation, a Seattle-Wash.-based cell therapy company, announced today that the U.S. Food and Drug Administration (FDA) has granted it Rare Pediatric Disease Designation (RPDD) for Iduronicrin genleukocel-T, Immusoft's Sleeping Beauty transposon-engineered autologous plasmablasts for the expression and delivery of alpha-L-iduronidase (IDUA) to treat Mucopolysaccharidosis type I (MPS I).
Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.
Many patients worldwide are going to receive major abdomen surgery or intestine transplantation every year and expect to be afflicted with liver injury afterwards.
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Two drugs tested in a larger trial did not improve kidney function in acute heart failure patients, contrary to results of smaller studies. The results were presented today at the American Heart Association's Scientific Sessions 2013 in Dallas and simultaneously published in the Journal of the American Medical Association. Previous smaller studies showed that low-dose dopamine or low-dose nesiritide could improve kidney function and reduce fluid overload that is often present in hospitalized acute heart failure patients by increasing urine production.
New statistics show a big increase in the number of cancers detected by breast screening. In 2003/04 over 14% more cancers were detected compared to the previous year with over 11,000 women having breast cancer detected and treated following screening for the disease. Since 2001 the total number of cancers detected through breast screening has risen by nearly a third.
Immusoft Corporation, a Seattle-Wash.-based cell therapy company, announced today that the U.S. Food and Drug Administration (FDA) has granted it Rare Pediatric Disease Designation (RPDD) for Iduronicrin genleukocel-T, Immusoft's Sleeping Beauty transposon-engineered autologous plasmablasts for the expression and delivery of alpha-L-iduronidase (IDUA) to treat Mucopolysaccharidosis type I (MPS I).
Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.
Many patients worldwide are going to receive major abdomen surgery or intestine transplantation every year and expect to be afflicted with liver injury afterwards.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 2 |
| Total Amount of Fines in Dollars | $17712 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 2 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 7.18 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 9.91 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 47.62 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.48 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 2.13 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 0 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.92 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 6.29 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 84.72 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.04 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 4.63 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 12.5 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 8.42 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.5 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 87.62 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 72.7 | 82.93 |
News Archive
Two drugs tested in a larger trial did not improve kidney function in acute heart failure patients, contrary to results of smaller studies. The results were presented today at the American Heart Association's Scientific Sessions 2013 in Dallas and simultaneously published in the Journal of the American Medical Association. Previous smaller studies showed that low-dose dopamine or low-dose nesiritide could improve kidney function and reduce fluid overload that is often present in hospitalized acute heart failure patients by increasing urine production.
New statistics show a big increase in the number of cancers detected by breast screening. In 2003/04 over 14% more cancers were detected compared to the previous year with over 11,000 women having breast cancer detected and treated following screening for the disease. Since 2001 the total number of cancers detected through breast screening has risen by nearly a third.
Immusoft Corporation, a Seattle-Wash.-based cell therapy company, announced today that the U.S. Food and Drug Administration (FDA) has granted it Rare Pediatric Disease Designation (RPDD) for Iduronicrin genleukocel-T, Immusoft's Sleeping Beauty transposon-engineered autologous plasmablasts for the expression and delivery of alpha-L-iduronidase (IDUA) to treat Mucopolysaccharidosis type I (MPS I).
Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.
Many patients worldwide are going to receive major abdomen surgery or intestine transplantation every year and expect to be afflicted with liver injury afterwards.
› Verified 6 days ago
Park Meadows Health And Rehabilitation Center Location: 3250 Sw 41st Place, Gainesville, Florida 32608 Phone: (352) 378-1558 | |
Plaza Health And Rehab Location: 4842 Sw Archer Road, Gainesville, Florida 32608 Phone: (352) 376-8821 | |
North Florida Rehabilitation And Specialty Care Location: 6700 Nw 10th Place, Gainesville, Florida 32605 Phone: (352) 331-3111 | |
Palm Garden Of Gainesville Location: 227 Sw 62nd Blvd, Gainesville, Florida 32607 Phone: (352) 331-0601 | |
Gainesville Health & Rehabilitation Location: 4000 Sw 20th Ave, Gainesville, Florida 32607 Phone: (352) 377-1981 |